Clarient Test for Ovarian Cancer May Predict Patient Response to Taxane Therapy (CLRT)
Wednesday, March 17, 2010 - 06:52
Written on Wed, 03/17/2010 - 6:52am
By Chip Brian

3/17/2010-Clarient's (NASDAQ:CLRT) test for ovarian cancer identified which patients may respond to taxane therapy in a study, which could spare some patients the side effects of the chemotherapy drugs, Dow Jones reported Wednesday.
The developer of cancer diagnostics presented the data Tuesday at the national meeting on women's cancer of the Society of Gynecologic Oncologists at the University of Alabama, Birmingham.
The test detects the expression of a substance called TLE3 in an ovarian tumor. In a study of 583 patients, the interaction test between TLE3 expression and response to taxane therapy was statistically significant.
Shares closed Tuesday at $2.65 after rising 8.6% and were inactive premarket.

Keywords: clarient ovarian Cancer taxane chemotherapy

Ticker(s): CLRT

Contact Chip Brian



Smartrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.mysmartrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at http://www.mysmartrend.com/morning-call-newsletter-signup.